Impact of procedural and patient-related risks on 1-year outcomes for patients treated with 1-month dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy after biodegradable-polymer drug-eluting stent implantation.
Shimada R, Ishida M, Takahashi F, Niiyama M, Ishisone T, Matsumoto Y, Taguchi Y, Osaki T, Nishiyama O, Endo H, Sakamoto R, Tanaka K, Koeda Y, Kimura T, Goto I, Ninomiya R, Sasaki W, Shimada K, Itoh T, Morino Y; REIWA investigators.
Shimada R, et al. Among authors: tanaka k.
Cardiovasc Interv Ther. 2025 Jan 17. doi: 10.1007/s12928-025-01087-9. Online ahead of print.
Cardiovasc Interv Ther. 2025.
PMID: 39822097